Welcome to the investor section of the site. The pages in this section of the website contain all information which is required to be disclosed in accordance with Rule 26 of the AIM Rules and can be accessed from the drop down menu of the Investors section.
In order to be aware of the latest news and events as they occur, we also encourage investors to subscribe to our email news alert service.
Futura Medical plc is committed to enhancing shareholder value through the development of innovative, over the counter products for the consumer healthcare market, focused on sexual healthcare and pain relief management.
The following agreements have been signed for our products:
CSD500 - a condom aimed at helping healthy men maintain a firmer erection during intercourse whilst wearing a condom. Global distribution agreement with SSL International plc ("SSL"). CSD500 is expected to be Futura's first product to market. In November 2008, CSD500 received a positive regulatory opinion relating to the pharmaceutical aspects of the dossier from the EU Competent Authority, which marks a pivotal step towards European marketing authorisation. In March 2010, SSL submitted the updated dossier for the European marketing authorisation of CSD500, with the CE Mark approval for the product expected later in 2010.
MED2002 - a non-prescription topical treatment for erectile dysfunction ("ED") - Global development and licensing agreement with SSL.
TPR100 - a topical treatment for the provision of pain relief using our DermaSys® technology. In June 2010, we signed a development agreement with GlaxoSmithKline plc (GSK) for the development and potential commercialisation of TPR100. GSK will fully fund and be responsible for all clinical activities leading to regulatory approvals. Subject to satisfactory clinical outcomes and regulatory approvals both parties expect to enter into a commercial distribution agreement in due course.
Our other drug products, which are not currently partnered, are:
PET500 - an over the counter topical product for men with premature ejaculation. Commercial discussions are ongoing.
RAD100 - a product which is designed to provide rapid local topical anaesthesia prior to injection, vaccination or cannulation.
In addition, we are evaluating the use of our proprietary delivery system DermaSys® with a range of other compounds.
Page last up-dated: 30 June 2010
Page last reviewed: 30 June 2010
Inheritance tax business property relief on Futura Medical shares -
To find out more please click here
